2026-10-14T14:07:04Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34026106 2026-09-29T17:28:17Z category_12 category_21 category_64 category_132 portal_5 item_type_1 month_year_09_2026

<p>Assessment of time to progression evidence.</p> Yu Xiao (150812) Jing Fu (177892) Juan Li (146180) Gang Hu (132827) Cell Biology Biotechnology Cancer Infectious Diseases required summary measures level summary statistics grade ae estimates available regimens differ analyzed exploratorily using 98 &# 8211 87 &# 8211 80 &# 8211 79 &# 8211 67 &# 8211 06 &# 8211 less favorable pfs analysis summarized pfs effect bayesian models connected overall networks bayesian network meta 24 &# 8211 19 &# 8211 16 ), ptn favorable survival profile xlink "> within highest confirmed orr analysis </ p indirect survival comparisons pneumonitis risk relative dominant survival networks compared therapies used xlink "> her2 dm1 vs lap xlink "> dominant pfs confirmed orr 19 ), pneumonitis networks targeted therapies sae comparisons nala network july 24 effects models survival ranking pneumonitis odds dominant trials treatment difference sparse sae quantitatively synthesized prespecified conversion phase ii odds ratios <p>(A) TTP-related comparisons identified from the eligible reports. PHOEBE could not be converted because the PTN-Cap upper 95% confidence limit was not reached, whereas the EMILIA/Welslau FACT-B time-to-symptom-worsening endpoint was clinically distinct from TTP and was excluded. (B) Reported PHOEBE medians are shown descriptively and were not converted to a mean difference.</p> <p>(TIF)</p> 2026-09-29T17:28:10Z Image Figure 10.1371/journal.pone.0358540.s005 https://figshare.com/articles/figure/_p_Assessment_of_time_to_progression_evidence_p_/34026106 CC BY 4.0